In 2006, neuroscientists from the Stanford Stroke Center published the results of the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. This NIH funded multicenter trial established that perfusion imaging findings can differentiate stroke patients who are likely to benefit from reperfusion therapies from those who are unlikely to benefit or may be harmed. However, at that time the technology available to process perfusion imaging studies was cumbersome, time-consuming, and poorly validated.

To address these limitations, Stanford Faculty members Greg Albers and Roland Bammer partnered with software engineer Matus Straka and Silicon Valley venture capitalist Don Valentine to develop RAPID, a fully automated image processing platform. RAPID was developed to provide accurate and reliable perfusion and diffusion imaging processing that could be performed on any CT or MRI scanner.

RAPID was initially validated in the NIH-sponsored DEFUSE 2 study, published in 2012. Stanford University sold the rights to RAPID to iSchemaView in 2012. FDA clearance of RAPID was granted in 2013. RAPID was shown to identify patients who benefit from endovascular stroke therapy in the SWIFT-PRIME and EXTEND-IA trials in 2015. Patients treated in these trials had the highest rates of favorable clinical outcomes following endovascular therapy ever achieved.